Come up with a name for your new list and we'll add to it:
Trius Therapeutics raised a round of funding on May 07, 2010. Investors include
Defense Threat Reduction Agency.
Trius Therapeutics is discovering and developing antibacterial drugs for the treatment of life-threatening infections. The company's lead product candidate, TR-701 is a oral and IV oxazolidinone antib…